Rajesh Janardhanan, MD
Internal Medicine · Tucson, AZNPI 1174796239
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $580,119 of the $684,963 with a category attached, or 84.7%. Philips North America LLC accounts for 61.9% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2020 at $166,294 and has fallen 69.3% since, to $51,109 in 2025. Among internal medicine clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 671 payments — averaging $1020.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Philips North America LLC$424K
- Lantheus Medical Imaging, Inc.$219K
- Astellas Pharma US Inc$21K
- E.r. Squibb & Sons, L.L.C.$19K
- Abbott$365
- Akcea Therapeutics, Inc.$197
- plus $961 from 10 others
Across 18 payments — averaging $16,551 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Lantheus Medical Imaging, Inc.$298K
What the payments were for
- Consulting fees$2,5750%
- Speaking & faculty fees$580,11985%
- Travel & lodging$88,18313%
- Food & beverage$14,0782%
- Education$80%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Philips North America LLC | 338 | $423,909 |
| Lantheus Medical Imaging, Inc. | 268 | $219,057 |
| Astellas Pharma US Inc | 18 | $20,987 |
| E.r. Squibb & Sons, L.L.C. | 25 | $19,488 |
| Abbott | 4 | $365 |
| Akcea Therapeutics, Inc. | 2 | $197 |
| Pfizer | 5 | $164 |
| Heartflow, Inc. | 2 | $161 |
| Edwards Lifesciences | 2 | $155 |
| Boehringer Ingelheim | 1 | $115 |
| Regeneron Healthcare Solutions, Inc. | 1 | $112 |
| Insulet Corporation | 1 | $106 |
| Canon Medical Systems USA, Inc. | 1 | $68 |
| GE HealthCare | 1 | $37 |
| Boston Scientific | 1 | $30 |
| Actelion Pharmaceuticals US, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Definity$215,288
- Educ Ultrasound$156,938
- (1658) Clinical Educ Ultrasound$131,561
- (7881) Ultrasound Und$57,141
- RS Ultrasound undiv$25,818
- Clin Educ US$25,532
- US Undivided Serv$23,787
- US Und$298
- EPIQ 7C$150
- MitraClip$130
- INSPIRIS RESILIA aortic valve$127
- TRICLIP$122
- TEGSEDI$122
- JARDIANCE$115
- PRALUENT$112
- CAMZYOS$110
- Omnipod$106
How this compares
$684,963 in reported general payments places this provider in the 95th percentile of 2,212 internal medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 55 | $76,699 |
| XareltoRivaroxaban | 19 | $24,293 |
| Midodrine Hcl | 22 | $4,602 |
| Droxidopa | 12 | $3,186 |
| Atorvastatin Calcium | 170 | $1,516 |
| Rosuvastatin Calcium | 72 | $1,059 |
| Metoprolol Succinate | 68 | $835 |
| Metoprolol Tartrate | 93 | $691 |
| Losartan Potassium | 77 | $636 |
| Ezetimibe | 20 | $606 |
| Carvedilol | 55 | $572 |
| Warfarin Sodium | 26 | $510 |
| Lisinopril | 88 | $486 |
| Amlodipine Besylate | 83 | $421 |
| Furosemide | 56 | $406 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $164 | $76,69955 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,212 internal medicine providers in Arizona.
Other internal medicine in Tucson
- Mona SelejTucson$440K
- Franz RischardTucson$55K
- Nebojsa SkrepnikTucson$48K
- Christine OxleyTucson$44K
- Muhammad HusnainTucson$19K
- Steven WoolTucson$19K
- Surekha BandlamuriTucson$17K
- Augusto PosadasTucson$15K
- Lisa EmmansTucson$14K
- Gary BohayTucson$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.